I would not much worry about outstanding partially paid shares at this stage. Previous Management and Chairman was responsible for that bad decision. They shouldn’t have accepted the partially paid shares in the first place.
I’ll prefer new Management and Board to focus and spend company cash on FDA 510K and commercialisation of products into existing regulatory approved region. It’s time to see some cash inflow too.
Company needs to be very very careful with the cash spend.
Ann: Medibio Quarterly Update and Cashflow Report, page-6
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
